Dowling & Yahnke’s Colgate-Palmolive CL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $3.98M | Buy |
56,586
+493
| +0.9% | +$38.7K | 0.19% | 118 |
|
|
2022
Q2 | $4.5M | Buy |
56,093
+49
| +0.1% | +$3.83K | 0.21% | 112 |
|
|
2022
Q1 | $4.25M | Buy |
56,044
+1,414
| +3% | +$112K | 0.18% | 124 |
|
|
2021
Q4 | $4.66M | Sell |
54,630
-1,889
| -3% | -$148K | 0.22% | 114 |
|
|
2021
Q3 | $4.27M | Sell |
56,519
-529
| -0.9% | -$42K | 0.24% | 115 |
|
|
2021
Q2 | $4.64M | Buy |
57,048
+654
| +1% | +$53.5K | 0.27% | 101 |
|
|
2021
Q1 | $4.45M | Buy |
56,394
+348
| +0.6% | +$27.3K | 0.3% | 97 |
|
|
2020
Q4 | $4.79M | Sell |
56,046
-115
| -0.2% | -$9.51K | 0.34% | 88 |
|
|
2020
Q3 | $4.33M | Sell |
56,161
-1,024
| -2% | -$78.1K | 0.35% | 84 |
|
|
2020
Q2 | $4.19M | Buy |
57,185
+3,442
| +6% | +$245K | 0.35% | 86 |
|
|
2020
Q1 | $3.57M | Buy |
53,743
+1,368
| +3% | +$96.5K | 0.34% | 79 |
|
|
2019
Q4 | $3.6M | Sell |
52,375
-766
| -1% | -$52.2K | 0.28% | 104 |
|
|
2019
Q3 | $3.91M | Sell |
53,141
-552
| -1% | -$40K | 0.32% | 96 |
|
|
2019
Q2 | $3.85M | Sell |
53,693
-2,287
| -4% | -$162K | 0.32% | 91 |
|
|
2019
Q1 | $3.84M | Sell |
55,980
-2,201
| -4% | -$142K | 0.37% | 80 |
|
|
2018
Q4 | $3.7M | Sell |
58,181
-1,762
| -3% | -$110K | 0.38% | 79 |
|
|
2018
Q3 | $4.01M | Sell |
59,943
-2,058
| -3% | -$137K | 0.35% | 90 |
|
|
2018
Q2 | $4.02M | Sell |
62,001
-6,649
| -10% | -$435K | 0.37% | 87 |
|
|
2018
Q1 | $4.92M | Sell |
68,650
-1,543
| -2% | -$111K | 0.46% | 72 |
|
|
2017
Q4 | $5.3M | Sell |
70,193
-682
| -1% | -$49.8K | 0.48% | 70 |
|
|
2017
Q3 | $5.16M | Sell |
70,875
-6,984
| -9% | -$503K | 0.52% | 69 |
|
|
2017
Q2 | $5.77M | Sell |
77,859
-254
| -0.3% | -$18.9K | 0.61% | 55 |
|
|
2017
Q1 | $5.72M | Sell |
78,113
-130
| -0.2% | -$9.1K | 0.61% | 57 |
|
|
2016
Q4 | $5.12M | Sell |
78,243
-1,176
| -1% | -$80.6K | 0.57% | 59 |
|
|
2016
Q3 | $5.89M | Buy |
79,419
+466
| +0.6% | +$34.4K | 0.69% | 46 |
|
|
2016
Q2 | $5.78M | Buy |
78,953
+1,089
| +1% | +$77.5K | 0.69% | 45 |
|
|
2016
Q1 | $5.5M | Buy |
77,864
+7,951
| +11% | +$529K | 0.68% | 48 |
|
|
2015
Q4 | $4.66M | Sell |
69,913
-45
| -0.1% | -$2.99K | 0.59% | 55 |
|
|
2015
Q3 | $4.44M | Buy |
69,958
+382
| +0.5% | +$25K | 0.6% | 57 |
|
|
2015
Q2 | $4.55M | Sell |
69,576
-191
| -0.3% | -$13K | 0.57% | 62 |
|
|
2015
Q1 | $4.84M | Buy |
69,767
+540
| +0.8% | +$37.3K | 0.6% | 55 |
|
|
2014
Q4 | $4.79M | Buy |
69,227
+18
| +0% | +$1.22K | 0.6% | 58 |
|
|
2014
Q3 | $4.51M | Buy |
69,209
+491
| +0.7% | +$32.4K | 0.59% | 57 |
|
|
2014
Q2 | $4.68M | Sell |
68,718
-8
| -0% | -$536 | 0.61% | 57 |
|
|
2014
Q1 | $4.46M | Buy |
68,726
+358
| +0.5% | +$22.6K | 0.59% | 60 |
|
|
2013
Q4 | $4.46M | Sell |
68,368
-396
| -0.6% | -$25.3K | 0.63% | 55 |
|
|
2013
Q3 | $4.08M | Sell |
68,764
-780
| -1% | -$46.2K | 0.64% | 54 |
|
|
2013
Q2 | $3.98M | Buy |
+69,544
| New | +$4.13M | 0.66% | 48 |
|
Other funds holding CL
TP
Dowling & Yahnke's CL Position: Q3 2022 in Review
Dowling & Yahnke increased its Colgate-Palmolive (CL) stake by 0.88% in Q3 2022, buying an estimated $38.7K and bringing the position to 56,586 shares worth $3.98M. The position accounts for 0.19% of the portfolio, ranked #118.
Dowling & Yahnke first reported a position in CL in Q2 2013 and has held it in 38 quarters since. The position peaked at $5.89M in Q3 2016. 1,615 funds tracked by Wall St. Rank hold CL as of Q3 2022.
- Dowling & Yahnke held 56,586 shares of Colgate-Palmolive worth $3.98M as of Q3 2022.
- Dowling & Yahnke bought 493 Colgate-Palmolive shares in Q3 2022, an estimated $38.7K.
- Colgate-Palmolive made up 0.19% of Dowling & Yahnke's portfolio in Q3 2022, its #118 holding.
- Dowling & Yahnke first reported a position in Colgate-Palmolive in Q2 2013 and has held it in 38 quarters since.
- Dowling & Yahnke's Colgate-Palmolive position peaked at $5.89M in Q3 2016.
- 1,615 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q3 2022.
Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.